Effect of treatment with recombinant human (rHu) interleukin‐4 (IL‐4) (10 ng·mL−1) on chronic beryllium disease (CBD) (n=5) bronchoalveolar lavage (BAL) cells' IL‐4 messenger ribonucleic acid (mRNA) production. IL‐4 mRNA is expressed as a ratio of IL‐4/β‐actin mRNA. Data presented as median (IQR) over time
| IL‐4/β‐actin mRNA ratio | Condition | |||
| Time | Unstimulated | rHu IL‐4 (10 ng·mL−1) | BeSO4 (100 μM) | rHu IL‐4 (10 ng·mL−1)/BeSO4 (100 μM) |
| 0 hours | 0 (0–0.01) | 0 (0–0.01) | 0.01 (0–0.02) | 0 (0–0.02) |
| 24 hours | 0 (0–0.01) | 0 (0–0.01) | 0 (0–0) | 0 (0–0.01) |
| 72 hours | 0 (0–0.02) | 0 (0–0.01) | 0 (0–0) | 0 (0–0.01) |
| 120 hours | 0 (0–0.01) | 0 (0–0.01) | 0 (0–0.01) | 0 (0–0.01) |